Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • In Brief
  • Published:

Transplantation

Avoiding a mismatch to limit GVHD

Nature Reviews Clinical Oncology volume 12, page 562 (2015)Cite this article

Subjects

Access through your institution
Buy or subscribe

Haematopoeitic-cell transplantation from unrelated donors is associated with acute graft-versus-host disease (GVHD), and this risk is increased when donor and recipient are HLA-DPB1 mismatched. Researchers explored the possibility that GVHD risk is correlated with the rs9277534 allele and HLA-DPB1 mismatch in recipients. They genotyped 3,503 patients and showed that HLA-DPB1 expression was influenced by the rs9277534 marker: rs9277534G (high-expression allele) was associated with a greater GVHD risk in recipients than those with the rs9277534A (low-expression allele).

This is a preview of subscription content, access via your institution

Access options

Access through your institution

Buy this article

  • Purchase on SpringerLink
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Petersdorf, E. W. et al. High HLA-DP expression and graft-versus-host disease. N. Engl. J. Med. 373, 599–609 (2015)

    Article  CAS  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Avoiding a mismatch to limit GVHD. Nat Rev Clin Oncol 12, 562 (2015). https://doi.org/10.1038/nrclinonc.2015.150

Download citation

  • Published:

  • Issue date:

  • DOI: https://doi.org/10.1038/nrclinonc.2015.150

Search

Advanced search

Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer